ArticleAmerican journal of translational research2019

Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification.

Seung Tae Kim et al.PubMed ↗Full text ↗

No numbers read from the abstract.